Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2868 + anlotinib + chemotherapy in pancreatic cancer
NCT06767813Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Mar 2024
- Primary completion
- Nov 2026
- Modality
- Immunotoxins, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of TQB2868 in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoint: Progression-Free Survival. Started Mar 2024; status: recruiting.
02
Drugs
TQB2868
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06767813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06767813.